amoxicillin + clavulanic acid
NDA- Indications
- Acute otitis media
Company intelligence / Profile preview
Kaizen Bioscience focuses on developing anti-infective solutions to combat infectious diseases with an emphasis on capital efficiency. Its lead program—a novel pediatric formulation of amoxicillin with reduced clavulanate—has completed a Phase 1 pharmacokinetic study and aims for NDA submission in the first half of 2025. The company leverages model-informed drug development and collaborates with academic partners to address unmet needs in pediatric infectious disease treatment.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kaizen Bioscience.